Browse by Phase
Phase 2 / Phase 3 Clinical Trials
Phase 2/3 combined trials bridge efficacy assessment and large-scale comparison, enrolling larger cohorts while still gathering dose-response data.
Total Trials
118
Recruiting Now
118
Top Conditions in Phase 2 / Phase 3
Frequently Asked Questions — Phase 2 / Phase 3 Trials
What distinguishes a Phase 2/3 combined trial?
Phase 2/3 combined trials bridge efficacy assessment and large-scale comparative confirmation in a single expanding protocol. The Phase 2 portion identifies optimal dosing and collects early efficacy signals, while the Phase 3 portion expands enrollment and applies the primary statistical analysis to a larger population. This design reduces time from dose selection to pivotal evidence.
How large are Phase 2/3 combined trials?
Phase 2/3 trials are larger than standalone Phase 2 studies but may be smaller than fully powered Phase 3 trials. Enrollment typically ranges from 200 to 1,000 participants, depending on the condition, endpoint, and statistical requirements. Interim analyses allow sample size adjustment if early results indicate more statistical power is needed.
Who benefits most from Phase 2/3 trial designs?
Phase 2/3 designs particularly benefit patients with serious or rare conditions where standard treatments are inadequate. Because the Phase 2 and Phase 3 portions run as one continuous protocol, patients who enroll in Phase 2 may transition into the Phase 3 portion without interruption—a continuity of care advantage compared to sequential separate studies.
Active Phase 2 / Phase 3 Studies
NCT05770037 Phase 2, Phase 3
Recruiting
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/You...
Condition
Haematological Malignancy
Enrollment
30 pts
Location
United Kingdom
Sponsor
Cancer Research UK
NCT07221357 Phase 2, Phase 3
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Che...
Condition
Untreated, Unresectable, or Metastatic Colorectal Cancer
Enrollment
990 pts
Location
United States, Argentina, Australia
Sponsor
Bristol-Myers Squibb
NCT07658534 Phase 2, Phase 3
Recruiting
A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Viru...
Condition
Respiratory Syncytial Virus Infections
Enrollment
290 pts
Location
China
Sponsor
Shanghai Ark Biopharmaceutical
NCT05254171 Phase 2, Phase 3
Recruiting
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Ca...
Condition
Pancreatic Cancer Metastatic
Enrollment
600 pts
Location
United States, Australia, Austria
Sponsor
Panbela Therapeutics, Inc.
NCT04419584 Phase 2, Phase 3
Recruiting
Evaluate the Efficacy of Using Modified Qing-Ying Decoction in Atopic Dermatitis...
Condition
Atopic Dermatitis
Enrollment
64 pts
Location
Hong Kong
Sponsor
Chinese University of Hong Kon
NCT07068165 Phase 2, Phase 3
Recruiting
A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the ...
Condition
IgG4 Related Disease
Enrollment
198 pts
Location
China
Sponsor
Peking Union Medical College H
NCT06028737 Phase 2, Phase 3
Recruiting
Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesopha...
Condition
Gastric Cancer
Enrollment
150 pts
Location
Lithuania, Ukraine
Sponsor
Ukrainian Society of Clinical
NCT06972511 Phase 2, Phase 3
Recruiting
Maximal Tumor Eradication for Oligometastatic Prostate Cancer
Condition
Oligometastatic Prostate Cancer
Enrollment
120 pts
Location
China
Sponsor
RenJi Hospital
NCT06785337 Phase 2, Phase 3
Recruiting
"The Effect of Inhaled Nitroglycerin for COPD Patients
Condition
COPD
Enrollment
40 pts
Location
Egypt
Sponsor
Beni-Suef University
NCT04061512 Phase 2, Phase 3
Recruiting
Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamid...
Condition
Waldenstrom Macroglobulinemia
Enrollment
148 pts
Location
United Kingdom
Sponsor
University College, London
NCT07266831 Phase 2, Phase 3
Recruiting
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have No...
Condition
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Enrollment
570 pts
Location
United States, Argentina, Canada
Sponsor
Merck Sharp & Dohme LLC
NCT07290595 Phase 2, Phase 3
Recruiting
Comparative Analysis Of Dexmedetomidine And Dexamethasone As An Adjuvant To 0.5%...
Condition
Post Operative Analgesia
Enrollment
66 pts
Location
Pakistan
Sponsor
Sahiwal medical college sahiwa
NCT05893888 Phase 2, Phase 3
Recruiting
A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subj...
Condition
Oral Squamous Cell Carcinoma
Enrollment
40 pts
Location
United States
Sponsor
Privo Technologies
NCT06739720 Phase 2, Phase 3
Recruiting
RCT of Efficacy and Safety of CP003 on CFS/ME or Post COVID-19 Fatigue
Condition
Chronic Fatigue Syndrome (CFS)
Enrollment
130 pts
Location
Hong Kong
Sponsor
The University of Hong Kong
NCT06644937 Phase 2, Phase 3
Recruiting
Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Thera...
Condition
Hepatocellular Carcinoma (HCC)
Enrollment
30 pts
Location
China
Sponsor
Zhujiang Hospital
NCT07204275 Phase 2, Phase 3
Recruiting
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants...
Condition
Primary Membranous Nephropathy
Enrollment
176 pts
Location
United States, Australia, Brazil
Sponsor
Vertex Pharmaceuticals Incorpo
NCT05062837 Phase 2, Phase 3
Recruiting
Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC
Condition
Hepatocellular Carcinoma
Enrollment
62 pts
Location
China
Sponsor
Guangxi Medical University
NCT06933914 Phase 2, Phase 3
Recruiting
Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysm...
Condition
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Enrollment
120 pts
Location
China
Sponsor
Wuhan Createrna Science and Te
NCT07063576 Phase 2, Phase 3
Recruiting
Effect of Baclofen in Management of Patients With Gastroesophageal Reflux Diseas...
Condition
GERD - PPI Non-responders
Enrollment
60 pts
Location
Bangladesh
Sponsor
Adnan Imtiaj Rahul
NCT06296082 Phase 2, Phase 3
Recruiting
Comparative Study of the Effects of Dry Needling and Botulinum Toxin Type A as a...
Condition
Stroke
Enrollment
90 pts
Location
Belgium, Canada, Spain
Sponsor
Universiteit Antwerpen
NCT05316935 Phase 2, Phase 3
Recruiting
GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atyp...
Condition
Endometrial Neoplasms
Enrollment
80 pts
Location
China
Sponsor
Xiaojun Chen
NCT07426094 Phase 2, Phase 3
Recruiting
PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation i...
Condition
Prostate Cancer
Enrollment
600 pts
Location
Poland
Sponsor
Affidea Nu-med Center of Oncol
NCT06125327 Phase 2, Phase 3
Recruiting
SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fi...
Condition
Idiopathic Pulmonary Fibrosis
Enrollment
210 pts
Location
China
Sponsor
Guangzhou JOYO Pharma Co., Ltd
NCT07282028 Phase 2, Phase 3
Recruiting
A Prospective, Open-label, Pivotal Study to Assess Spectacle Hearing Aid Safety ...
Condition
Hearing Loss Mixed
Enrollment
89 pts
Location
Israel
Sponsor
Nuance Hearing
NCT05587036 Phase 2, Phase 3
Recruiting
Effects of Rifaximin on Gut Microbiota and Emotion
Condition
Healthy Volunteers
Enrollment
60 pts
Location
Belgium
Sponsor
Universitaire Ziekenhuizen KU
Page 1 of 5 — 118 trials total
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology